Thyroid hormone receptor-α and vascular function

American Journal of Physiology - Cell Physiology

Volumn 302, Issue 9, 2012, Pages

  Makino, Ayako ^a,b   Wang, Hong ^b   Scott, Brian T ^b   Yuan, Jason X J ^a,b   Dillmann, Wolfgang H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Coronary artery; Knockout mouse; Potassium channel; Vascular contraction

Indexed keywords

LIOTHYRONINE; POTASSIUM CHANNEL; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; HEART CONTRACTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ANIMALS; BLOTTING, WESTERN; CORONARY VESSELS; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MICE; MICE, KNOCKOUT; PATCH-CLAMP TECHNIQUES; POLYMERASE CHAIN REACTION; THYROID HORMONE RECEPTORS ALPHA; TRIIODOTHYRONINE;

MUS;

EID: 84860499029     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00292.2011     Document Type: Article

References (61)

1. Abe A, Yamamoto T, Isome M, Ma M, Yaoita E, Kawasaki K, Kihara I, Aizawa Y. Thyroid hormone regulates expression of Shaker-related potassium channel mRNA in rat heart. Biochem Biophys Res Commun 245: 226-230, 1998.
2. Adachi T. Modulation of vascular sarco/endoplasmic reticulum calcium ATPase in cardiovascular pathophysiology. Adv Pharmacol 59: 165-195, 2010.
3. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol, chapt 15, unit 15.18, 2006.
4. 2+ channels. Science 302: 1416-1418, 2003.
5. Davis PJ, Zhou M, Davis FB, Lansing L, Mousa SA, Lin HY. Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol Behav 99: 237-239, 2010.
6. de Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27: 1908-1920, 2006.
7. Degens H, Gilde AJ, Lindhout M, Willemsen PH, Van Der Vusse GJ, Van Bilsen M. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am J Physiol Heart Circ Physiol 284: H108-H115, 2003.
8. Feletou M, Vanhoutte PM. EDHF: an update. Clin Sci (Lond) 117: 139-155, 2009.
9. Figueroa XF, Chen CC, Campbell KP, Damon DN, Day KH, Ramos S, Duling BR. Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone? Am J Physiol Heart Circ Physiol 293: H1371-H1383, 2007.
10. Flamant F, Samarut J. Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 14: 85-90, 2003.
11. Gassanov N, Er F, Michels G, Zagidullin N, Brandt MC, Hoppe UC. Divergent regulation of cardiac KCND3 potassium channel expression by the thyroid hormone receptors α1 and β1. J Physiol 587: 1319-1329, 2009.
12. Gauthier K, Chassande O, Plateroti M, Roux JP, Legrand C, Pain B, Rousset B, Weiss R, Trouillas J, Samarut J. Different functions for the thyroid hormone receptors TRα and TRβ in the control of thyroid hormone production and post-natal development. EMBO J 18: 623-631, 1999.
13. Gloss B, Trost S, Bluhm W, Swanson E, Clark R, Winkfein R, Janzen K, Giles W, Chassande O, Samarut J, Dillmann W. Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor-α or -β. Endocrinology 142: 544-550, 2001.
14. Hansen JB. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13: 361-376, 2006.
15. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen NH, Scanlan TS, Moskowitz MA, Cheng SY, Liao JK. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103: 14104-14109, 2006.
16. Hu Y, Pang Z, Yang Z, Wei W, Wu Y. Study of the catalytic effect of PAR on the luminol-potassium ferricyanide reaction using a flow-injection chemiluminescence method. Luminescence 20: 25-29, 2005.
17. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107: 708-713, 2003.
18. Ishikawa T, Chijiwa T, Hagiwara M, Mamiya S, Hidaka H. Thyroid hormones directly interact with vascular smooth muscle strips. Mol Pharmacol 35: 760-765, 1989.
19. Johansson C, Gothe S, Forrest D, Vennstrom B, Thoren P. Cardiovascular phenotype and temperature control in mice lacking thyroid hormone receptor-β or both α1 and β. Am J Physiol Heart Circ Physiol 276: H2006-H2012, 1999.
20. Judge SI, Smith PJ. Patents related to therapeutic activation of Katp and K2P potassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics. Expert Opin Ther Pat 19: 433-460, 2009.
21. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 26: 704-728, 2005.
22. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RC, Tawadrous MF, Lowes BA, Long CS, Bristow MR. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103: 1089-1094, 2001.
23. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89: 591-598, 2001.
24. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509, 2001.
25. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J Clin Endocrinol Metab 78: 1026-1027, 1994.
26. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333: 1522-1527, 1995.
27. + channels in mouse pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 293: C928-C937, 2007.
28. Kobayashi K, Akune H, Sumida K, Saito K, Yoshioka T, Tsuji R. Perinatal exposure to PTU decreases expression of Arc, Homer 1, Egr 1 and Kcna 1 in the rat cerebral cortex and hippocampus. Brain Res 1264: 24-32, 2009.
29. Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med 88: 638-641, 1990.
30. Ma ML, Watanabe K, Watanabe H, Hosaka Y, Komura S, Aizawa Y, Yamamoto T. Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats. Jpn Heart J 44: 101-110, 2003.
31. Mai W, Janier MF, Allioli N, Quignodon L, Chuzel T, Flamant F, Samarut J. Thyroid hormone receptor-α is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101: 10332-10337, 2004.
32. Makino A, Platoshyn O, Suarez J, Yuan JX, Dillmann WH. Down-regulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice. Am J Physiol Cell Physiol 295: C221-C230, 2008.
33. Makino A, Suarez J, Wang H, Belke DD, Scott BT, Dillmann WH. Thyroid hormone receptor- β is associated with coronary angiogenesis during pathological cardiac hypertrophy. Endocrinology 150: 2008-2015, 2009.
34. Mansen A, Tiselius C, Sand P, Fauconnier J, Westerblad H, Rydqvist B, Vennstrom B. Thyroid hormone receptor-a can control action potential duration in mouse ventricular myocytes through the KCNE1 ion channel subunit. Acta Physiol (Oxf) 198: 133-142, 2010.
35. Millanvoye-Van Brussel E, David-Dufilho M, Pham TD, Iouzalen L, Aude Devynck M. Regulation of arachidonic acid release by calcium influx in human endothelial cells. J Vasc Res 36: 235-244, 1999.
36. + channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol 1: 251-258, 2003.
37. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 88: 313-318, 2001.
38. Moreno JM, Wangensteen R, Sainz J, Rodriguez-Gomez I, Chamorro V, Osuna A, Vargas F. Role of endothelium-derived relaxing factors in the renal response to vasoactive agents in hypothyroid rats. Am J Physiol Endocrinol Metab 285: E182-E188, 2003.
39. Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37: 1137-1146, 2004.
40. Morkin E, Pennock GD, Spooner PH, Bahl JJ, Goldman S. Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 12: 527-533, 2002.
41. Motomura K, Brent GA. Mechanisms of thyroid hormone action. Implications for the clinical manifestation of thyrotoxicosis. Endocrinol Metab Clin North Am 27: 1-23, 1998.
42. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46: 356-360, 2005.
43. Mustapha M, Fang Q, Gong TW, Dolan DF, Raphael Y, Camper SA, Duncan RK. Deafness and permanently reduced potassium channel gene expression and function in hypothyroid Pit1dw mutants. J Neurosci 29: 1212-1223, 2009.
44. Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, Fazio S, Sacca L. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 104: 3076-3080, 2001.
45. Nishiyama A, Kambe F, Kamiya K, Seo H, Toyama J. Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. Cardiovasc Res 40: 343-351, 1998.
46. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6: 505-512, 1996.
47. Owen PJ, Sabit R, Lazarus JH. Thyroid disease and vascular function. Thyroid 17: 519-524, 2007.
48. Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris C, Malliopoulou V, Cokkinos DV. Thyroid hormone receptors-α1 and - β1 are down regulated in the post infarcted rat heart: consequences on the response to ischaemia reperfusion. Basic Res Cardiol 100: 422-432, 2005.
49. Pantos C, Mourouzis I, Xinaris C, Kokkinos AD, Markakis K, Dimo-poulos A, Panagiotou M, Saranteas T, Kostopanagiotou G, Cokkinos DV. Time-dependent changes in the expression of thyroid hormone receptor-α1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodeling. Eur J Endocrinol 156: 415-424, 2007.
50. Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 85: 734-738, 1997.
51. Pingitore A, Iervasi G, Barison A, Prontera C, Pratali L, Emdin M, Giannessi D, Neglia D. Early activation of an altered thyroid hormone profile in asymptomatic or mildly symptomatic idiopathic left ventricular dysfunction. J Card Fail 12: 520-526, 2006.
52. + channel isoforms in rat ventricle. J Physiol 500: 65-73, 1997.
53. Stoykov I, Zandieh-Doulabi B, Moorman AF, Christoffels V, Wiers-inga WM, Bakker O. Expression pattern and ontogenesis of thyroid hormone receptor isoforms in the mouse heart. J Endocrinol 189: 231-245, 2006.
54. Streeten DH, Anderson GH Jr, Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 11: 78-83, 1988.
55. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Salvetti A, Ferrannini E, Monzani F. Impaired endothelium-dependent vasodilatation in sub clinical hypothyroidism: beneficial effect of levothy roxine therapy. J Clin Endocrinol Metab 88: 3731-3737, 2003.
56. Theilen EO, Wilson WR. Hemodynamic effects of peripheral vasoconstriction in normal and thyrotoxic subjects. J Appl Physiol 22: 207-210, 1967.
57. Walker JD, Crawford FA, Kato S, Spinale FG. The novel effects of 3,5,3'-triiodo-L-thyronine on myocyte contractile function and β-adrener-gic responsiveness in dilated cardiomyopathy. J Thorac Cardiovasc Surg 108: 672-679, 1994.
58. Wang X, Zheng W, Christensen LP, Tomanek RJ. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 284: H613-H618, 2003.
59. Watanabe H, Ma M, Washizuka T, Komura S, Yoshida T, Hosaka Y, Hatada K, Chinushi M, Yamamoto T, Watanabe K, Aizawa Y. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun 308: 439-444, 2003.
60. Wickenden AD, Kaprielian R, You XM, Backx PH. The thyroid hormone analog DITPA restores Ito in rats after myocardial infarction. Am J Physiol Heart Circ Physiol 278: H1105-H1116, 2000.
61. Wikstrom L, Johansson C, Salto C, Barlow C, Campos Barros A, Baas F, Forrest D, Thoren P, Vennstrom B. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor-α1. EMBO J 17: 455-461, 1998.